抑制Rac1蛋白活化阻碍胚胎发育早期血管新生

小G蛋白Rac1在胚胎发育早期血管形成尤其是内皮发生过程中的作用尚不清楚．采用胚胎干细胞(ESCs)为模型,建立稳定表达持续表达型Rac1(G12V)和显性失活型Rac1(T17N)编码序列的小鼠ESCs并制备胚胎小体(EBs),诱导分化后观察Rac1(G12V)和Rac1(T17N)对内皮细胞分化和迁移功能的影响．采用相差显微镜观察EBs发育和分化特征,Pull down分析Rac1表达变化,免疫荧光染色和Western blot分析内皮分化标志物,Matrigel凝胶实验观察血管索形成．结果表明,无论过表达或抑制Rac1的活化,并不影响EBs发育,均可形成典型的EBs胚层结构．抑制Rac1活化对内皮细胞系的发育无影响,但分化的内皮细胞不能连接成血管网．活化的Rac1表达减少,细胞迁移受到明显抑制．抑制Rac1活化导致细胞骨架F-actin排布紊乱．以上结果提示,Rac1影响胚胎早期血管发育的因素是抑制细胞游走,后者可能是通过F-actin机制所介导．     

原花青素B2通过Akt/FoxO4通路拮抗内皮细胞衰老的实验研究

研究原花青素B2(PCB2)对内皮细胞衰老的调控作用,探讨其可能的分子机制。以棕榈酸(PA)50μmol/L处理胰岛内皮细胞MS-1建立细胞衰老模型,根据细胞活力、β-半乳糖苷酶(SA-β-Gal)染色以及细胞周期相关基因的表达来评估内皮细胞衰老;同时加入PCB2干预,检测衰老相关指标及Akt/FoxO4通路的蛋白表达水平的变化情况。MS-1细胞经PA处理后SA-β-Gal阳性细胞增加,细胞周期相关基因p53和p21上调显示细胞周期阻滞在G0/G1期,表明PA处理后能诱导内皮细胞衰老发生;经PCB2(50μg/mL)干预后能够有效改善PA诱导的细胞衰老。相比于正常组,经PA处理后抑制Akt活化,其表达由胞核转至胞浆,在胞核中表达明显减少;导致Akt下游信号FoxO4的磷酸化降低,使其在细胞核中明显增加;而应用PCB2(50μg/mL)处理后能有效逆转这一现象;PCB2对棕榈酸诱导的内皮细胞衰老有明显的保护作用,其可能通过Akt/FoxO4信号通路发挥调控作用。     

大蒜素激活SIRT1通路抑制过氧化氢诱导人脐静脉内皮细胞的衰老

Sirtuin1(SIRT1)活性的异常与血管内皮细胞的衰老密切相关。大蒜素作为一种生物活性分子具有抗氧化、抗炎及调脂作用,然而目前尚未见关于大蒜素与SIRT1的活性调节的报道。本研究旨在阐明大蒜素对过氧化氢（H2O2）诱导人脐静脉内皮细胞（HUVECs）衰老的影响,以及Sirtuin1(SIRT1)在其中的作用。SA-β-gal染色及活性氧检测提示,与对照组相比,大蒜素明显减少H2O2诱导半乳糖苷酶阳性细胞数及活性氧的产生。用Western印迹、MTT、RT-PCR及SIRT1活化检测对SIRT1、p-SIRT1、PAI-1的蛋白质、SIRT1mRNA表达及细胞活力进行检测,结果显示,大蒜素可以逆转H2O2诱导的PAI-1表达的升高、SIRT1磷酸化及活性的降低,并且上调细胞的活力。当采用SIRT1抑制剂NAM处理后,大蒜素的这些作用均被阻断。以上结果表明,大蒜素通过激活SIRT1抑制H2O2诱导的HUVECs ROS的产生、活力的下降及细胞的衰老。     

达格列净对高渗诱导的血管内皮细胞衰老的干预研究

目的:探讨SGLT2i类药物达格列净(dapagliflozin)对高渗诱导的人脐静脉内皮细胞(HUVECs)衰老的影响。方法:将HUVECs分为空白组(Blank组)、高渗330组(M-330组)、高渗350组(M-350组)、达格列净+高渗组(DAPA+M-350组),高渗培养环境由甘露醇诱导。衰老相关β-半乳糖苷酶(SA-β-Gal)染色检测细胞衰老情况;免疫荧光染色检测SGLT2表达变化;Western blot检测SGLT2、细胞衰老标志物p21的表达变化,JC-1染色试剂盒检测线粒体膜电位的变化。结果:免疫荧光染色和western blot结果显示,Blank组,M-330组及M-350组细胞上均存在SGLT2受体蛋白表达,且Blank组,M-330组及M-350组的SGLT2表达依次显著增加。与Blank组相比,M-350组SA-β-Gal胞质蓝染、染色阳性率、衰老蛋白p21及SGLT2表达显著增加,并伴有线粒体膜电位的显著下降(P0.05);DAPA+M-350组与M-350组相比,SA-β-Gal胞质蓝染、染色阳性率和p21表达显著下降,并伴有线粒体膜电位的显著上升(P0.05)。结论:HUVECs上存在SGLT2受体蛋白,且在300-350 m Osm/L范围内随着渗透压的升高而增加,达格列净可改善高渗所诱导的血管内皮细胞衰老,其机制可能与达格列净改善高渗导致的线粒体功能障碍有关。     

AFAP1在博来霉素诱导的A549细胞衰老中的作用机制研究

目的:研究AFAP1在博来霉素诱导的A549细胞衰老模型中的作用及分子机制。方法:用50μg/m L的博来霉素处理A549细胞5天建立细胞衰老模型。用相同浓度的博来霉素处理细胞1-5天观察细胞从周期阻滞到衰老的过程,SA-β-Gal染色检测衰老细胞数目,用Western blot方法检测AFAP1、p21、c-Src等蛋白表达。过表达AFAP1后,观察细胞衰老状态及各蛋白表达水平变化。结果:50μg/m L的博来霉素处理A549细胞5天后可以建立细胞衰老模型,表现为BLM组SA-β-Gal阳性细胞数升高(P0.01)且细胞体积显著增大(P0.01),p21表达水平升高。在衰老的A549细胞中,AFAP1和激活型(Src p Y416)表达水平变化一致,从BLM处理后出现升高第4天开始明显下降在第5天最低,c-Src和Src p Y527表达水平不变。过表达AFAP1后再用博来霉素诱导,SA-β-Gal阳性细胞数及细胞体积、Src p Y416和p21表达与空载对照比较未发现有明显差异(P0.05)。结论:衰老的A549细胞中AFAP1表达下调,c-Src活性降低;过表达AFAP1不能减轻博来霉素诱导的A549细胞衰老,也不能抑制衰老细胞中的c-Src的活性下降。     

Rac1/MAPK/ERK 通路介导脂多糖LPS 诱导的人内皮细胞 单层通透性增高机制研究

目的:探讨LPS诱导的人内皮细胞单层通透性改变的分子机制。方法:应用逆转录病毒为载体,感染并筛选稳定表达持续活化型Rac1和主导抑制型Rac1的人HUVEC细胞,应用LPS刺激并观察细胞骨架蛋白F-actin和HUVEC单层通透性的改变。同时应用Western blot方法检测LPS刺激前后细胞中MAPK/ERK信号通路的改变及加入PD98059阻断ERK表达后,细胞内F-actin的改变情况。结果:与正常HUVEC相比较,LPS刺激后,感染活化型Rac1和主导抑制型Rac1的HUVEC中F-actin重构并形成大量应力纤维,细胞单层通透性显著增加。而抑制型Rac1感染后的HUVEC中F-actin无重构现象,同时细胞单层通透性无明显增加。LPS刺激前后,各组细胞中ERK1/2总蛋白均无明显改变。LPS刺激后,感染活化型Rac1的HUVEC中,p-ERK增加。经PD98059阻断后,细胞内p-ERK表达下降同时伴随F-actin解聚发生。结论:LPS诱导的内皮细胞通透性增加是经过Rac1-MAPK/ERK通路介导的。     

HMG盒转录因子1(HBP1)参与H2O2诱导的细胞衰老过程

为探讨HMG盒转录因子1 (HBP1)在过氧化氢（H2O2）诱导的细胞衰老中所起的作用,通过慢病毒感染得到稳定表达HBP1的MDA-MB-231细胞,以H2O2处理细胞．采用Western免疫印迹杂交试验和实时PCR检测HBP1、p16和细胞周期蛋白D1（cyclinD1）表达水平的变化．用荧光免疫试验检测H2O2对HBP1表达的影响,以及HBP1在H2O2的诱导下对于p16和细胞周期蛋白D1启动子的影响．用细胞增殖试验检测H2O2对于细胞增殖的影响． 用基因敲减实验和衰老相关β半乳糖苷酶(SA-β-Gal)染色检测在H2O2诱导的细胞衰老中HBP1所起的作用．Western和免疫荧光实验结果显示,细胞经H2O2处理后,HBP1表达增高的同时促进了p16的表达,降低了细胞周期蛋白D1的表达．细胞增殖实验结果显示,H2O2显著抑制了细胞的增殖．基因敲减实验和SA-β-Gal染色实验说明,H2O2可诱导HBP1表达正常的MDA-MB-231细胞衰老,而HBP1的敲减则抑制了H2O2诱导的细胞衰老过程．本研究结果提示,在H2O2诱导的衰老中,HBP1的表达显著增加,并通过促进衰老相关基因p16的表达和抑制生长因子cyclinD1的表达来阻碍细胞增殖,促进细胞衰老．HBP1在H2O2诱导的细胞衰老过程中起着重要作用,H2O2诱导的细胞衰老必须在HBP1存在的情况下才能发生．     

转录因子HBP1调控H2O2诱导的骨肉瘤细胞生长阻滞过程

为探讨氧化应激对人骨肉瘤细胞增殖的影响及其作用机理,首先用H2O2处理U2OS细 胞,采用Western印迹和real-time PCR检测HMG盒转录因子1 (HBP1)及其下游靶基因 DNMT1和p16表达水平的变化. 用荧光素酶报告基因实验检测在H2O2诱导下, HBP1对于DNMT1 和p16启动子的影响. 用细胞增殖试验（BrdU掺入,细胞生长曲线）检测 H2O2对细胞增殖的影响以及HBP1的作用. 用衰老相关β半乳糖苷酶(SA-β-Gal)染色 检测在H2O2诱导的细胞衰老中HBP1所起的作用. Western 印迹, real-time PCR及荧光素酶报告基因实验结果显示,细胞经H2O2处理后,明显增高HBP1表达水平,转录抑制DNMT1的表达, 促进p16蛋白的表达. 细胞增殖实验结果显示, H2O2显著抑制了细胞的增殖,HBP1 knockdown可部分逆转这种抑制作用. SA-β-Gal染色实验说明, H2O2可诱导HBP1表达正常的U2OS细胞衰老,而HBP1 knockdown使这种促衰老作用减弱. 研究结果说明, H2O2可抑制人骨肉瘤细胞增殖,诱导细胞衰老. 其作用机制是通过上调转录因子HBP1的表达,转录抑制或促进其下游靶基因DNMT1或p16的表达来抑制细胞增殖,促进细胞衰老.     

衰老对AhR 及其血管生成相关因子表达的影响

目的:探讨芳香烃受体(aryl hydrocarbon receptor,Ah R)在过氧化氢(H_2O_2)诱导的人脐静脉内皮细胞(HUVECs)衰老模型中表达的变化情况及其对血管生成相关因子表达的影响。方法:采用不同浓度的H_2O_2(100μM,200μM,300μM)处理HUVECs诱导内皮细胞衰老,通过β-半乳糖苷酶染色观察细胞衰老情况,Western blot检测HUVECs中Ah R蛋白以及血管生成相关因子低氧诱导因子-1α(hypoxia-inducible factor-1α,HIF-1α)蛋白表达,ELISA检测细胞培养上清液中血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的变化。结果:与对照组相比,经过不同浓度H_2O_2处理后,HUVECs均出现细胞衰老表现,Ah R蛋白表达显著增加,HIF-1α以及VEGF蛋白表达明显减少,且均呈现出剂量依赖性,以300μM H_2O_2处理组最为显著。结论:在过氧化氢诱导衰老的人脐静脉内皮细胞中Ah R蛋白表达明显增加,HIF-1α和VEGF等促血管生成因子明显减少。     

G蛋白偶联雌激素受体介导17β-雌二醇抗血管平滑肌细胞氧化应激性衰老

目的探讨G蛋白偶联雌激素受体(GPER)能否介导雌激素抗大鼠血管平滑肌细胞(vascular smooth muscle cells,VSMCs)氧化应激性衰老效应。方法取体外培养第3~4代VSMCs,以150μmol/L H_2O_2处理2h建立细胞衰老模型。用10~(-8)mol/L17β-雌二醇(E_2)、10~(-6)mol/LGPER激动剂G1和抑制剂G15分别处理VSMCs。衰老相关β-半乳糖苷酶(SA-β-Gal)染色法检测各组细胞SA-β-Gal染色阳性率;流式细胞术检测各组细胞周期变化;RT-qPCR和Western blot检测GPERmRNA和蛋白表达变化。结果 H_2O_2使VSMCs SA-β-Gal染色阳性率明显增加,细胞周期停滞于G0/G1期,GPER mRNA和蛋白水平降低,E2和G1对H_2O_2的这些效应具有抑制作用,而G15可阻断E2和G1对H_2O_2上述效应的抑制作用。结论雌激素依赖GPER发挥抗血管平滑肌细胞氧化应激性衰老效应。     

Cellular senescence requires CDK5 repression of Rac1 activity

Cellular senescence is a tumor-suppressive process characterized by an irreversible cell cycle exit, a unique morphology, and expression of senescence-associated beta-galactosidase (SA-beta-Gal). We report here a role for CDK5 in induction of senescent cytoskeletal changes. CDK5 activation is upregulated in senescing cells. The increased activity of CDK5 further reduces GTPase Rac1 activity and Pak activation. The repression of the activity of the GTPase Rac1 by CDK5 is required for expression of the senescent phenotype. CDK5 regulation of Rac1 activity is necessary for actin polymerization accompanying senescent morphology in response to expression of pRb, activated Ras, or continuous passage. Inhibition of CDK5 attenuates SA-beta-Gal expression and blocks actin polymerization. These results point to a unique, nonneuronal role for CDK5 in regulation of Rac1 activity in senescence, illuminating the mechanisms underlying induction of senescence and the senescent shape change.     

Cell cycle arrest by human cytomegalovirus 86-kDa IE2 protein resembles premature senescence

Primary human embryo lung fibroblasts and adult diploid fibroblasts infected by the human cytomegalovirus (HCMV) display beta-galactosidase (beta-Gal) activity at neutral pH (senescence-associated beta-Gal [SA-beta-Gal] activity) and overexpression of the plasminogen activator inhibitor type 1 (PAI-1) gene, two widely recognized markers of the process designated premature cell senescence. This activity is higher when cells are serum starved for 48 h before infection, a process that speeds and facilitates HCMV infection but that is insufficient by itself to induce senescence. Fibroblasts infected by HCMV do not incorporate bromodeoxyuridine, a prerequisite for the formal definition of senescence. At the molecular level, cells infected by HCMV, beside the accumulation of large amounts of the cell cycle regulators p53 and pRb, the latter in its hyperphosphorylated form, display a strong induction of the cyclin-dependent kinase inhibitor (cdki) p16(INK4a), a direct effector of the senescence phenotype in fibroblasts, and a decrease of the cdki p21(CIP1/WAF). Finally, a replicative senescence state in the early phases of infection significantly increased the number of cells permissive to virus infection and enhanced HCMV replication. HCMV infection assays carried out in the presence of phosphonoformic acid, which inhibits the virus DNA polymerase and the expression of downstream genes, indicated that immediate-early and/or early (alpha) genes are sufficient for the induction of SA-beta-Gal activity. When baculovirus vectors expressing HCMV IE1-72 or IE2-86 proteins were inoculated into fibroblasts, the increase of p16(INK4a) (observed predominantly with IE2-86) was similar to that observed with the whole virus, as was the induction of SA-beta-Gal activity, suggesting that the viral IE2 gene leads infected cells into senescence. Altogether our results demonstrate for the first time that HCMV, after arresting the cell cycle and inhibiting apoptosis, triggers the cellular senescence program, probably through the p16(INK4a) and p53 pathways.     

Ginsenoside Rb1 Prevents H2O2-Induced HUVEC Senescence by Stimulating Sirtuin-1 Pathway

Purposes

We have previously reported that Ginsenoside Rb1 may effectively prevent HUVECs from senescence, however, the detailed mechanism has not demonstrated up to now. Recent studies have shown that sirtuin-1 (Sirt1) plays an important role in the development of endothelial senescence. The purpose of this study was to explore whether Sirt1 is involved in the action of Ginsenoside Rb1 regarding protection against H₂O₂-induced HUVEC Senescence.

Methods and Results

Senescence induced by hydrogen peroxide (H₂O₂) in human umbilical vein endothelial cells (HUVECs) was examined by analyzing plasminogen activator inhibitor-1 (PAI-1) expression, cell morphology, and senescence-associated beta-galactosidase (SA-β-gal) activity. The results revealed that 42% of control-treated HUVECs were SA-β-gal positive after treatment by 60 µmol/L H₂O₂, however, this particular effect of H₂O₂ was decreased more than 2-fold (19%) in the HUVECs when pretreated with Rb1 (20 µmol/L) for 30 min. Additionally, Rb1 decreased eNOS acetylation, as well as promoted more NO production that was accompanied by an increase in Sirt1 expression. Furthermore, upon knocking down Sirt1, the effect of Rb1 on HUVEC senescence was blunted.

Conclusions

The present study indicated that Ginsenoside Rb1 acts through stimulating Sirt1 in order to protect against endothelial senescence and dysfunction. As such, Sirt1 appears to be of particular importance in maintaining endothelial functions and delaying vascular aging.     

血清反应因子参与RhoA诱导的人血管内皮细胞肌动蛋白骨架重构

为进一步阐明RhoA调控人脐静脉内皮细胞(human umbilical vein endothelial cell,HUVEC)肌动蛋白骨架重构的分子机制,用逆转录病毒感染并筛选出稳定表达持续活化型RhoA(Q63LRhoA)和主导抑制型RhoA(T19NRhoA)的HUVECs。应用免疫组化和Western blot方法分析去血清前后HUVECs血清反应因子(serum response factor,SRF)的表达及定位,Rhodamine-Phalloidine染色观察F-actin动态变化。结果显示,Q63LRhoA组细胞核中SRF表达增加,F-actin重排形成大量应力纤维;T19NRhoA组中SRF表达较弱,F-actin无明显改变,无应力纤维形成。去血清后,正常HUVECs(对照组)和感染细胞中SRF的表达均显著增加,但其亚细胞定位明显不同。对照组去血清培养3d,SRF主要定位在细胞核,去血清培养5d,SRF出核转位入细胞浆。Q63LRhoA组SRF发生核滞留,不随去血清培养时间延长发生出核转位现象。T19NRhoA组SRF的表达主要定位于细胞核周。对照组去血清培养3d,F-actin表达增加,同时形成大量应力纤维,去血清培养5d,细胞F-actin表达下调,应力纤维解聚。Q63LRhoA组F-actin重构持续发生并形成大量应力纤维,但不随去血清培养时间延长发生明显解聚。而T19NRhoA组F-actin表达不随去血清时间延长而增加。上述结果提示,RhoA介导HUVECs F-actin的重构与SRF的核转位现象密切相关。     

Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells

Immunogold EM was employed to compare the distribution of type 1 plasminogen activator inhibitor (PAI-1) on the surface of agonist-activated human umbilical vein endothelial cells (HUVECs) with that of control, unactivated cells. As previously observed, (Schleef, R.R., T.J. Podor, E. Dunne, J. Mimuro, and D.J. Loskutoff. J. Cell Biol. 110:155-163), analysis of cross-sections of nonpermeabilized control HUVEC monolayers stained first with affinity-purified rabbit antibodies to PAI-1 and then with gold-conjugated goat anti-rabbit IgG, revealed the presence of relatively few gold particles (less than 1-2% of the total) on the apical cell surface. The majority of gold particles were detected primarily in the extracellular matrix between the culture substratum and the cell membrane. In contrast, treatment of HUVECs with tumor necrosis factor alpha (TNF alpha; 200 U/ml, 24 h) or with lipopolysaccharide (LPS; 10 micrograms/ml, 24 h) resulted in an increased staining of PAI-1 not only in the extracellular matrix, but also on the apical cell surface (10-fold increase). Immunoabsorption of the rabbit anti-PAI-1 with purified PAI-1, or treatment of HUVECs with tissue-type plasminogen activator (2.5 micrograms/ml, 2 h, 4 degrees C) reduced the amount of staining both on the apical surface and in the extracellular matrix of agonist-activated HUVECs by 80-95%. The topographical location of PAI-1 on the cell surface was examined further by coupling immunogold staining with high resolution surface replication. Transmission EM of surface replicas from TNF alpha- or LPS-activated HUVECs revealed a general increase in PAI-1 staining both on planar regions and within indentations of the apical cell surface. Nonactivated HUVECs revealed PAI-1-specific immunogold particles only in areas of exposed extracellular matrix between the cells and occasionally at regions of cell-cell contacts. Analysis of activated bovine aortic endothelial cells by immuno-electron microscopy, immunologic assays, and flow cytometry revealed similar increases in surface PAI-1. These increases in surface PAI-1 could be detected by 3 h and continued over a 24-h period. The expression of PAI-1 on the luminal surface of endothelial cells during immune or inflammatory reactions could reduce endothelial fibrinolytic activity, thus, promoting the localized, pathologic formation of intravascular thrombi.     

Hypoxia-induced expression of complement receptor type 1(CR1, CD35) in human vascular endothelial cells

Reoxygenation of hypoxic human umbilical vein endothelial cells(HUVECs) increases protein expression of the complement regulators CD46and CD55. As the receptor for C3b is known to be present on injuredbovine endothelial cells, we investigated whether hypoxia or inflammatory mediators induce complement receptor type 1 (CR1; CD35) expression on HUVECs. CR1 protein expressionincreased 3.7 ± 0.6-fold as measured by ELISA on HUVECsfollowing hypoxia (48 h, 1%O₂). Colocalization of CD35 andvon Willebrand factor by confocal microscopy confirmed that CD35 waspredominantly intracellular. Lipopolysaccharide or tumor necrosisfactor- also significantly increased HUVEC CR1 proteinexpression. Western blot analysis of neutrophil or hypoxicHUVEC lysates revealed a 221-kDa CR1 band under nonreducingconditions. RT-PCR of hypoxic HUVEC mRNA revealed a singleband that, after sequencing, was identified as CD35. In situhybridization of hypoxic HUVECs, but not normoxic HUVECs or fibroblasts, demonstrated increased CD35 mRNA.Hypoxic HUVECs bound immune complexes and acted as a cofactorfor factor I-mediated cleavage of C3b. Thus hypoxia induces functionalHUVEC CR1 expression.     

The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator

The interactions between exogenously added tissue-type plasminogen activator (t-PA) and the active form of type 1 plasminogen activator inhibitor (PAI-1) produced by and present in cultured human umbilical vein endothelial cells (HUVECs) were investigated. Immunoblotting analysis of the conditioned media obtained from monolayers of HUVECs treated with increasing concentrations of t-PA (less than or equal to 10 micrograms/ml) revealed a dose-dependent formation of both t-PA/PAI-1 complexes, and of a 42,000-Mr cleaved or modified form of the inhibitor. Immunoradiometric assays indicated that t-PA treatment resulted in a fourfold increase in PAI-1 antigen present in the conditioned media. This increase did not result from the release of PAI-1 from intracellular stores, but rather reflected a t-PA-dependent decrease in the PAI-1 content of the Triton X-100 insoluble extracellular matrix (ECM). Although the rate of t-PA-mediated release of PAI-1 was increased by the removal of the monolayer, similar quantities of PAI-1 were removed in the presence or absence of the cells. These results suggest that the cells only represent a semipermeable barrier between ECM-associated PAI-1 and exogenous t-PA. Treatment of HUVECs with t-PA (1 microgram/ml, 2 h) to deplete the ECM of PAI-1 did not affect the subsequent rate of PAI-1 production and deposition into the ECM. Immunogold electron microscopy of HUVECs not only confirmed the location of PAI-1 primarily in the region between the culture substratum and ventral cell surface but failed to demonstrate significant (less than 1%) PAI-1 on the cell surface. Thus, the majority of PAI-1 associated with cultured HUVEC monolayers is present under the cells in the ECM and is accessible to solution-phase t-PA.